

3rd January, 2022

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051

Scrip Code: BSE - 524500

Scrip Code: NSE - KILITCH

Sub: Disclosure Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Dear Sir,

In continuation of disclosure dated 31st December, 2022 submitted pursuant to provisions of regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, details of the Kilitch Estro Biotech equity, foreign subsidiary of the company shares of which are being acquired are mentioned herein below;

Particulars	Details	
Name of the target entity	Kilitch Estro Biotech PLC	
Turnover (Rs.)	31st March, 2022 9,44,85,529	21st March, 2021 54,25,327.86
Whether related party transaction	Yes	
Whether Promoter / Promoter Group/ Group Companies have any interest?	Mr. Mukund Mehta, Promoter and Mr. Bhavin Mehta, Promoter Group of the Company are directors of Kilitch Estro Biotech PLC	
Whether the transaction is on arm's length basis ?	Yes	
Industry to which the entity being acquired belongs	Pharmaceutical	
Object and effects of acquisition	To enhance investment of Kilitch Drugs (India) limited for long term return of investment	
Governmental or Regulatory approvals required for the acquisition	No prior approval is required.	
Indicative time period for completion of the acquisition	3- 6 months.	
Nature of Consideration	Cash Consideration	
Cost of Acquisition	Rs. 2,22,09,160	
Number of Shares acquired	14,436 shares	
Brief Background of the Company	Kilitch Estro Biotech PLC is engaged in manufacturing of Pharmaceutical Products	



WHO CERTIFIED



	incorporated in September, 2015 in Ethiopia, commenced its production in January, 2022
Pre and Post percentage of holding	67%. There is no change in percentage of holding of the Company because shares in same proportion is to be issued to other existing shareholders of Kilitch Estro Biotech PLC as well.

We request you to kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

Mukund Mehta
Managing Director

